Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock

Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100$0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31$119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3$611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1$0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].